190.40
8.11 (4.45%)
| Previous Close | 182.29 |
| Open | 184.07 |
| Volume | 222,076 |
| Avg. Volume (3M) | 226,656 |
| Market Cap | 5,475,999,232 |
| Price / Earnings (TTM) | 107.57 |
| Price / Earnings (Forward) | 31.95 |
| Price / Sales | 21.70 |
| Price / Book | 5.77 |
| 52 Weeks Range | |
| Earnings Date | 24 Feb 2025 - 28 Feb 2025 |
| Profit Margin | 21.68% |
| Operating Margin (TTM) | 41.67% |
| Diluted EPS (TTM) | 1.78 |
| Quarterly Revenue Growth (YOY) | 879.90% |
| Quarterly Earnings Growth (YOY) | -66.30% |
| Total Debt/Equity (MRQ) | 0.84% |
| Current Ratio (MRQ) | 7.97 |
| Operating Cash Flow (TTM) | 63.34 M |
| Levered Free Cash Flow (TTM) | 42.38 M |
| Return on Assets (TTM) | 4.58% |
| Return on Equity (TTM) | 6.38% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Mixed | Mixed |
| Biotechnology (Global) | Mixed | Mixed | |
| Stock | Krystal Biotech, Inc. | Bearish | Bullish |
AIStockmoo Score
| Analyst Consensus | 1.0 |
| Insider Activity | NA |
| Price Volatility | 2.0 |
| Technical Moving Averages | 0.0 |
| Technical Oscillators | 4.0 |
| Average | 1.75 |
|
Krystal Biotech Inc is engaged in the healthcare sector in the United States. It is focused on the development of easy-to-use, redosable gene therapies to improve the lives of patients living with debilitating diseases. The company used its proprietary gene therapy platform, STAR-D to develop treatments for rare or orphan dermatological indications caused by the absence of or a mutation in a single gene. It plans to leverage its platform to expand its pipeline to include other dermatological indications in the future. The company has one operating segment, which is the business of developing and commercializing pharmaceutical products. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| Investment Style | Small Growth |
| % Held by Insiders | 12.30% |
| % Held by Institutions | 106.12% |
| 52 Weeks Range | ||
| Price Target Range | ||
| High | 221.00 (HC Wainwright & Co., 16.07%) | Buy |
| Median | 220.00 (15.55%) | |
| Low | 206.00 (Citigroup, 8.19%) | Hold |
| Average | 215.67 (13.27%) | |
| Total | 2 Buy, 1 Hold | |
| Avg. Price @ Call | 182.54 | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| Citigroup | 05 Nov 2024 | 206.00 (8.19%) | Hold | 174.41 |
| HC Wainwright & Co. | 05 Nov 2024 | 221.00 (16.07%) | Buy | 174.41 |
| Stifel | 11 Sep 2024 | 220.00 (15.55%) | Buy | 198.79 |
No data within this time range.
| Date | Type | Details |
|---|---|---|
| 27 Nov 2024 | Announcement | Krystal Biotech to Present at Upcoming Investor Conferences |
| 12 Nov 2024 | Announcement | Krystal Biotech to Present at Stifel 2024 Healthcare Conference |
| 06 Nov 2024 | Announcement | Krystal Biotech to Present at Guggenheim Securities Healthcare Innovation Conference |
| 04 Nov 2024 | Announcement | Krystal Biotech Announces Third Quarter 2024 Financial Results and Provides Business Updates |
| 28 Oct 2024 | Announcement | Krystal Biotech to Report Third Quarter 2024 Financial Results on November 4, 2024 |
| 13 Sep 2024 | Announcement | Krystal Biotech to Present at 2024 Cantor Global Healthcare Conference |
| 06 Sep 2024 | Announcement | Krystal Biotech to Present at H.C. Wainwright 26th Annual Global Investment Conference |
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2024 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |